Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients

Crawford, Darrell H. G., Dore, Gregory J., Sievert, William, Cheng, Wendy S. C., Weltman, Martin, McCaughan, Geoffrey, Rawlinson, William, Marks, Philippa S., Yoshihara, Motoko, Rizkalla, Bishoy, Roberts, Stuart K. and the CHARIOT Study Group (2012) Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. Antiviral Therapy, 17 5: 849-854. doi:10.3851/IMP2104

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Crawford, Darrell H. G.
Dore, Gregory J.
Sievert, William
Cheng, Wendy S. C.
Weltman, Martin
McCaughan, Geoffrey
Rawlinson, William
Marks, Philippa S.
Yoshihara, Motoko
Rizkalla, Bishoy
Roberts, Stuart K.
the CHARIOT Study Group
Total Author Count Override 12
Title Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients
Journal name Antiviral Therapy   Check publisher's open access policy
ISSN 1359-6535
2040-2058
Publication date 2012-01-01
Sub-type Article (original research)
DOI 10.3851/IMP2104
Volume 17
Issue 5
Start page 849
End page 854
Total pages 6
Place of publication London, United Kingdom
Publisher International Medical Press
Collection year 2013
Language eng
Formatted abstract
Background: On-treatment HCV viral load during early therapy with pegylated interferon (PEG-IFN) and ribavirin is highly predictive of sustained virological response (SVR). We sought to provide further refinement of this prediction through an extensive evaluation of the effect of HCV viral loads at weeks 4, 8 and 12 on SVR, including analysis by liver disease stage grouping.

Methods: A total of 309 patients with genotype 1 chronic HCV and recent liver biopsy enrolled in the CHARIOT study received 180 mg of PEG-IFN-α2a weekly with 1,000/1,200 mg of ribavirin daily. The probability of an SVR was estimated using baseline METAVIR fibrosis stage and HCV viral loads at weeks 4, 8 and 12.

Results: HCV RNA was undetectable in 27.5%, 50.3% and 62.6% of patients at weeks 4, 8 and 12, respectively. SVR was 80.0%, 76.8% and 72.4% among patients with undetectable HCV RNA at weeks 4, 8 and 12, respectively. SVR decreased in a progressive fashion with increasing HCV viral loads at each early time point, but was similar for patients with HCV viral load <15 IU/ml, 15-100 IU/ml and 100-1,000 IU/ml. The effect of fibrosis stage on SVR was modest for patients with HCV viral load <1,000 IU/ml at week 4, but more marked for those with week 4 HCV viral load >1,000 IU/ml, and all HCV viral load categories at weeks 8 and 12.

Conclusions: A combination of baseline fibrosis stage and on-treatment HCV viral load at early time points provides improved estimates for treatment response in patients with chronic HCV genotype 1.
Keyword Sustained virological response
SVR
Pegylated interferon
PEG-IFN
HCV
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 16 Dec 2012, 10:14:37 EST by System User on behalf of School of Medicine